Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Valutazione di Lasofoxifene in combinazione con Abemaciclib rispetto a Fulvestrant in combinazione con Abemaciclib nel carcinoma mammario ER+/HER2- localmente avanzato o metastatico con mutazione ESR1 (ELAINEIII)

10 novembre 2026 aggiornato da: LeonaBio

Uno studio in aperto, randomizzato, multicentrico che confronta l'efficacia e la sicurezza dell'associazione di Lasofoxifene e Abemaciclib con l'associazione di Fulvestrant e Abemaciclib per il trattamento di donne e uomini in pre e postmenopausa con carcinoma mammario ER+/HER2- localmente avanzato o metastatico con una mutazione ESR1

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation.

The main question the study aims to answer is:

• To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

600

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Simon Daggett - Senior Vice President, Clinical Operations
  • Numero di telefono: (425) 620-8772 (909) 374-3793
  • Email: clinicaltrials@leonabio.com

Luoghi di studio

      • Blacktown, Australia
      • Concord, Australia
      • South Brisbane, Australia
        • Reclutamento
        • Mater Misericordiae Ltd, South Brisbane
        • Contatto:
    • Ontario
      • Ottawa, Ontario, Canada
        • Reclutamento
        • The Ottawa General Hospital
        • Contatto:
      • Toronto, Ontario, Canada
        • Reclutamento
        • Sunnybrook Health Sciences Centre -Bayview Campus
        • Contatto:
    • Quebec
      • Montreal, Quebec, Canada
      • Montreal, Quebec, Canada
      • Saguenay, Quebec, Canada
        • Ritirato
        • CIUSSS du Saguenay-Lac-Saint-Jean
      • Anhui, Cina
        • Reclutamento
        • Anhui Provincial Cancer Hospital
        • Contatto:
      • Anyang, Cina
      • Beijing, Cina
        • Reclutamento
        • Peking Union Medical College Hospital
        • Contatto:
      • Beijing, Cina
        • Reclutamento
        • Beijing Cancer Hospital
        • Contatto:
      • Bengbu, Cina
        • Reclutamento
        • The First Affiliated Hospital of Bengbu Medical University
        • Contatto:
      • Changchun, Cina
        • Reclutamento
        • The First Hospital of Jilin University
        • Contatto:
      • Changsha, Cina
        • Reclutamento
        • The Second Xiangya Hospital of Central South University
        • Contatto:
      • Chengdu, Cina
        • Reclutamento
        • Sichuan Provincial People's Hospital
        • Contatto:
      • Chengdu, Cina
        • Reclutamento
        • West China Hospital, Sichuan University
        • Contatto:
      • Chongqicun, Cina
        • Reclutamento
        • The First Affiliated Hospital, Chongqing Medical University
        • Contatto:
      • Dalian, Cina
        • Reclutamento
        • The Second Hospital of Dalian Medical University
        • Contatto:
      • Deyang, Cina
        • Reclutamento
        • Deyang People's Hospital
        • Contatto:
      • Fuyang, Cina
        • Reclutamento
        • Fuyang Cancer Hosptial
        • Contatto:
      • Fuzhou, Cina
        • Reclutamento
        • Fujian Cancer Hospital
        • Contatto:
      • Fuzhou, Cina
        • Reclutamento
        • Fujian Medical University Union Hospital
        • Contatto:
      • Guandong, Cina
        • Reclutamento
        • Zhujiang Hospital of Nanfang Medical University
        • Contatto:
      • Guangdong, Cina
        • Reclutamento
        • Guangdong Provincial People's Hospital
        • Contatto:
      • Guangdong, Cina
        • Reclutamento
        • Meizhou People's Hospital
        • Contatto:
      • Guangdong, Cina
        • Reclutamento
        • Peking University Shenzhen Hospital
        • Contatto:
          • Xiaoling Liu
      • Guangdong, Cina
        • Reclutamento
        • Sun Yat-Sen University- Cancer Center
        • Contatto:
      • Guangzhou, Cina
        • Reclutamento
        • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
        • Contatto:
      • Haikou, Cina
        • Reclutamento
        • The First Affiliated Hospital of Hainan Medical University
        • Contatto:
      • Hangzhou, Cina
        • Reclutamento
        • The First Affiliated Hospital, College of Medicine, Zhejiang University
        • Contatto:
      • Hangzhou, Cina
        • Reclutamento
        • Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
        • Contatto:
      • Hangzhou, Cina
        • Reclutamento
        • Zhejiang Provincial Hospital of Chinese Medicine
        • Contatto:
      • Hebei, Cina
        • Reclutamento
        • Hebei Medical University - The Fourth Hospital - Hebei Provincial Tumor Hospital
        • Contatto:
      • Hubei, Cina
        • Reclutamento
        • Xiangyang Central Hospital
        • Contatto:
      • Hunan, Cina
        • Reclutamento
        • Xiangya Hospital Central South University
        • Contatto:
      • Jieyang, Cina
        • Reclutamento
        • Jieyang People's Hospital
        • Contatto:
      • Jinan, Cina
        • Reclutamento
        • Shandong Province Tumor Hospital
        • Contatto:
      • Kunming, Cina
        • Reclutamento
        • Yunnan Cancer Hospital
        • Contatto:
      • Lanzhou, Cina
        • Reclutamento
        • The First Hospital of Lanzhou University
        • Contatto:
      • Lanzhou, Cina
        • Reclutamento
        • Gansu Provincial Hospital
        • Contatto:
      • Linyi, Cina
        • Reclutamento
        • Linyi Cancer Hospital
        • Contatto:
      • Luoyang, Cina
        • Reclutamento
        • The First Affiliated Hospital of Henan University of Science and Technology
        • Contatto:
      • Luoyang, Cina
        • Reclutamento
        • Luoyang Central Hospital
        • Contatto:
      • Luzhou, Cina
        • Reclutamento
        • The Affiliated Hospital of Southwest Medical University (Luzhou Medical College)
        • Contatto:
      • Nanchang, Cina
        • Reclutamento
        • Jiangxi Cancer Hospital
        • Contatto:
      • Nanchang, Cina
        • Reclutamento
        • Nanchang People's Hospital
        • Contatto:
      • Nanjing, Cina
        • Reclutamento
        • Nanjing Drum Tower Hospital
        • Contatto:
      • Nanjing, Cina
        • Reclutamento
        • Jiangsu Province Hospital - The First Affiliated Hospital with Nanjing Medical University
        • Contatto:
      • Nanning, Cina
        • Reclutamento
        • Guangxi Medical University Cancer Hospital
        • Contatto:
      • Nanyang, Cina
        • Reclutamento
        • Nanyang Central Hospital
        • Contatto:
      • Neijiang, Cina
        • Reclutamento
        • The Second People's Hospital of Neijiang
        • Contatto:
      • Ningbo, Cina
        • Reclutamento
        • Ningbo Medical Center Li Huili Hospital
        • Contatto:
      • Pingdingshan, Cina
        • Reclutamento
        • The First People'S Hospital of Ping Ding Shan
        • Contatto:
      • Qingdao, Cina
        • Reclutamento
        • The Affiliated Hospital of Qingdao University
        • Contatto:
      • Qingdao, Cina
        • Reclutamento
        • Qingdao Central Hospital, University of Health and Rehabilitation Sciences
        • Contatto:
      • Quanzhou, Cina
        • Reclutamento
        • Quanzhou First Hospital
        • Contatto:
      • Shanghai, Cina
        • Reclutamento
        • Huashan Hospital, Fudan University
        • Contatto:
      • Shanghai, Cina
        • Reclutamento
        • Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
        • Contatto:
      • Shang’ai, Cina
        • Reclutamento
        • Fudan University Cancer Center
        • Contatto:
      • Shanxi, Cina
        • Reclutamento
        • First Affiliated Hospital of Xi'an Jiaotong University
        • Contatto:
      • Shaoyang, Cina
        • Reclutamento
        • The Central Hospital of Shaoyang
        • Contatto:
      • Shenyang, Cina
        • Reclutamento
        • Liaoning Cancer Hospital & Institute
        • Contatto:
      • Shouguang, Cina
        • Reclutamento
        • Yuebei People's Hospital
        • Contatto:
      • Sichuan, Cina
        • Reclutamento
        • University of Electonic Science & Technology (UESTC) - Sichuan Cancer Hospital & Institute
        • Contatto:
      • Tianjin, Cina
        • Reclutamento
        • Tianjin Medical University Cancer Institute & Hospital
        • Contatto:
      • Tianjin, Cina
        • Reclutamento
        • Tianjin Cancer Hospital Airport Hospital
        • Contatto:
      • Wenzhou, Cina
        • Reclutamento
        • The First Affiliated Hospital of Wenzhou Medical University
        • Contatto:
      • Wuhan, Cina
        • Reclutamento
        • Hubei Cancer Hospital
        • Contatto:
      • Wuhan, Cina
        • Reclutamento
        • Union Hospital Tongji Medical College Huazhong University of Science and Technolog
        • Contatto:
      • Wuhu, Cina
        • Reclutamento
        • The Second People's Hospital of WuHu
        • Contatto:
      • Xi Ail, Cina
        • Reclutamento
        • The First Affiliated Hospital of Air Force Medical University
        • Contatto:
      • Xiamen, Cina
        • Reclutamento
        • Zhongshang Hospital Xiamen University
        • Contatto:
      • Xiamen, Cina
        • Reclutamento
        • The first affiliated hospital of Xiamen University
        • Contatto:
      • Xinzheng, Cina
        • Reclutamento
        • The Second Affiliated Hospital Of Xi'an Jiaotong University
        • Contatto:
      • Xuzhou, Cina
        • Reclutamento
        • The Affiliated Hospital of Xuzhou Medical University
        • Contatto:
      • Xuzhou, Cina
        • Reclutamento
        • Xuzhou Central Hospital
        • Contatto:
      • Yuncheng, Cina
        • Reclutamento
        • Yuncheng Central Hospital
        • Contatto:
      • Zhejiang, Cina
        • Reclutamento
        • Zhejiang Provincial People's Hospital
        • Contatto:
      • Zhejiang, Cina
        • Reclutamento
        • Zhejiang cancer hospital
        • Contatto:
      • Zhengzhou, Cina
        • Reclutamento
        • Henan Cancer Hospital
        • Contatto:
      • Zhengzhou, Cina
        • Reclutamento
        • The First Affiliated Hospital of Zhengzhou University
        • Contatto:
      • Zhongshan, Cina
        • Reclutamento
        • Zhongshan City People's Hospital
        • Contatto:
      • Zhumadian, Cina
        • Reclutamento
        • Zhumadian Central Hospital
        • Contatto:
      • Ürümqi, Cina
        • Reclutamento
        • The Affiliated Cancer Hospital of Xinjiang Medical University
        • Contatto:
      • Gyeonggi-do, Corea del Sud
        • Reclutamento
        • National Cancer Center
        • Contatto:
      • Jeollanam-do, Corea del Sud, 58128
        • Reclutamento
        • Chonnam National University Hwasun Hospital
        • Contatto:
      • Seoul, Corea del Sud
        • Reclutamento
        • Korea University Anam Hospital
        • Contatto:
      • Seoul, Corea del Sud
        • Ritirato
        • Severance Hospital, Yonsei University Health System
      • Seoul, Corea del Sud
        • Ritirato
        • Asan Medical Center
      • Dresden, Germania
      • München, Germania
        • Reclutamento
        • Klinikum rechts der Isar der Technischen Universitaet Muenchen
        • Contatto:
      • Afula, Israele, 1834111
      • Beersheba, Israele, 8486614
      • Haifa, Israele
      • Jerusalem, Israele
      • Jerusalem, Israele
        • Reclutamento
        • Hadassah Ein-Karem Medical Center
        • Contatto:
      • Kfar Saba, Israele, 4428164
      • Petah Tikva, Israele
      • Rehovot, Israele
        • Reclutamento
        • Kaplan Medical Center
        • Contatto:
      • Tel Aviv, Israele
        • Reclutamento
        • Tel Aviv Sourasky Medical Center
        • Contatto:
      • Tel HaShomer, Israele
      • Ancona, Italia
      • Aviano, Italia
      • Candiolo, Italia, 10060
      • Meldola, Italia
        • Reclutamento
        • IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST S.r.l.
        • Contatto:
      • Milan, Italia
      • Misterbianco, Italia
        • Reclutamento
        • Humanitas Istituto Clinico Catanese
        • Contatto:
      • Modena, Italia
        • Reclutamento
        • Azienda Ospedaliero-Universitaria di Modena
        • Contatto:
      • Naples, Italia
      • Novara, Italia, 28100
        • Ritirato
        • Azienda Ospedaliero Universitaria Maggiore Della Carita
      • Padova, Italia, 35128
        • Reclutamento
        • Istituto Oncologico Veneto-I.R.C.C.S. - Ospedale Busonera
        • Contatto:
      • Parma, Italia
      • Pavia, Italia
        • Reclutamento
        • Fondazione IRCCS Policlinico San Matteo
        • Investigatore principale:
          • Gianpiero Rizzo
        • Contatto:
      • Roma, Italia
      • Verona, Italia
        • Completato
        • Azienda Ospedaliera Universitaria Integrata Verona-Ospedale Borgo Trento
      • Biała Podlaska, Polonia
        • Ritirato
        • KO - MED Centra Kliniczne Sp. z o.o., Wojewodzki Szpital Specjalistyczny w Bialej Podlaskiej
      • Gliwice, Polonia
        • Ritirato
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach, I Klinika Radioterapii i Chemioterapii
      • Krakow, Polonia
        • Reclutamento
        • Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie - Oddzial Onkologii Klinicznej z Pododdzialem Dziennym
        • Contatto:
      • Krakow, Polonia
      • Lodz, Polonia
        • Completato
        • Instytut Centrum Zdrowia Matki Polki - Klinika Onkologii
      • Poznan, Polonia
        • Reclutamento
        • Uniwersytecki Szpital Kliniczny w Poznaniu, Oddzial Chemioterapii
        • Contatto:
      • Poznan, Polonia
        • Reclutamento
        • Wielkopolskie Centrum Onkologii (WCO) / The Greater Poland Cancer Center
        • Contatto:
      • Wieliszew, Polonia
      • Cardiff, Regno Unito, CF14 2TL
      • Harlow, Regno Unito, CM20 1QX
        • Reclutamento
        • Princess Alexandra Hospital - Harlow
        • Contatto:
      • Leeds, Regno Unito
      • London, Regno Unito
        • Reclutamento
        • Charing Cross Hospital
        • Contatto:
      • London, Regno Unito, NW3 2
        • Reclutamento
        • Royal Free London NHS Foundation Trust
        • Contatto:
      • Manchester, Regno Unito
      • Milton Keynes, Regno Unito, MK6 5LD
      • Nottingham, Regno Unito
      • Stockton-on-Tees, Regno Unito, TS198PE
        • Ritirato
        • University Hospital of North Tees
      • Bucharest, Romania
        • Reclutamento
        • Memorial Healthcare International SRL
        • Contatto:
      • Bucharest, Romania
        • Ritirato
        • Centrul Medical Focus
      • Cluj-Napoca, Romania
      • Craiova, Romania
        • Reclutamento
        • Oncology Center Sfantul Nectarie
        • Contatto:
      • Craiova, Romania
        • Completato
        • Onco Clinic Consult SA
      • Piteşti, Romania
      • Timișoara, Romania
        • Reclutamento
        • OncoMed Oncology Center
        • Contatto:
      • Singapore, Singapore, 329563
      • Barcelona, Spagna
        • Reclutamento
        • Hospital Universitario Vall d'Hebron
        • Contatto:
          • Miriam Arumi de Dios
          • Numero di telefono: +34600240679
          • Email: marumi@vhio.net
      • Barcelona, Spagna
      • Córdoba, Spagna
        • Reclutamento
        • Hospital Universitario Reina Sofia
        • Contatto:
      • Madrid, Spagna, 28034
        • Reclutamento
        • Hospital Universitario Ramon y Cajal
        • Contatto:
      • Madrid, Spagna, 28040
      • Madrid, Spagna
        • Reclutamento
        • Hospital Universitario 12 de Octubre
        • Contatto:
      • Madrid, Spagna
      • Madrid, Spagna
        • Reclutamento
        • Clinica Universidad de Navarra - Madrid
        • Contatto:
      • Madrid, Spagna
        • Reclutamento
        • Hospital Beata Maria Ana
        • Contatto:
      • Madrid, Spagna
        • Reclutamento
        • Hospital General Universitario Gregorio Maranon
        • Contatto:
      • Málaga, Spagna
      • Pamplona, Spagna
        • Reclutamento
        • Clinica Universidad de Navarra - Pamplona
        • Contatto:
      • Valencia, Spagna
        • Reclutamento
        • Instituto Valenciano de Oncologia
        • Contatto:
    • Arizona
      • Scottsdale, Arizona, Stati Uniti, 85259
        • Reclutamento
        • Mayo Clinic - Scottsdale
        • Contatto:
          • Clinical Trials Office - All Mayo Clinic Locations
          • Numero di telefono: 855-776-0015
      • Tucson, Arizona, Stati Uniti, 85719
        • Reclutamento
        • University of Arizona - Cancer Center
        • Contatto:
    • California
      • Santa Rosa, California, Stati Uniti, 95403
        • Reclutamento
        • Providence Medical Foundation - Santa Rosa, CA
        • Contatto:
    • Florida
      • Jacksonville, Florida, Stati Uniti, 32224
        • Reclutamento
        • Mayo Clinic - Jacksonville
        • Contatto:
          • Clinical Trials Office - All Mayo Clinic Locations
          • Numero di telefono: 855-776-0015
      • Miami, Florida, Stati Uniti, 33143
      • Plantation, Florida, Stati Uniti, 33324
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30322
    • Kentucky
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21231
        • Reclutamento
        • Johns Hopkins Kimmel Cancer Center
        • Contatto:
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02114
      • Boston, Massachusetts, Stati Uniti, 02215
        • Completato
        • Beth Israel Deaconess Medical Center
      • Boston, Massachusetts, Stati Uniti, 02115
    • Michigan
      • Grand Rapids, Michigan, Stati Uniti, 49503
        • Reclutamento
        • Cancer and Hematology Centers of Western Michigan
        • Contatto:
    • Minnesota
      • Minneapolis, Minnesota, Stati Uniti, 55407
        • Completato
        • Allina Health System DBA Virginia Piper Cancer Institute
      • Rochester, Minnesota, Stati Uniti, 55905
        • Reclutamento
        • Mayo Clinic - Rochester
        • Contatto:
          • Clinical Trials Office - All Mayo Clinic Locations
          • Numero di telefono: 855-776-0015
    • Missouri
      • Kansas City, Missouri, Stati Uniti, 64111
        • Reclutamento
        • Saint Luke's Cancer Institute
        • Contatto:
      • St Louis, Missouri, Stati Uniti, 63110
        • Reclutamento
        • Washington University School of Medicine
        • Contatto:
    • Nevada
      • Reno, Nevada, Stati Uniti, 89502
      • Reno, Nevada, Stati Uniti, 89511-2250
    • New Jersey
      • Belleville, New Jersey, Stati Uniti, 07109
        • Ritirato
        • New Jersey Cancer Care, PA
      • New Brunswick, New Jersey, Stati Uniti, 08901
    • New Mexico
      • Albuquerque, New Mexico, Stati Uniti, 87110
        • Non ancora reclutamento
        • Presbyterian Kaseman Hospital
        • Contatto:
      • Rio Rancho, New Mexico, Stati Uniti, 87124
        • Reclutamento
        • Presbyterian Rust Cancer Center
        • Contatto:
    • New York
      • New York, New York, Stati Uniti, 10029
        • Reclutamento
        • Icahn School of Medicine at Mount Sinai
        • Contatto:
      • New York, New York, Stati Uniti, 10065
        • Reclutamento
        • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
        • Contatto:
      • New York, New York, Stati Uniti, 10011
        • Reclutamento
        • The Blavatnik Family - Chelsea Medical Center at Mount Sinai
        • Contatto:
    • North Carolina
      • Durham, North Carolina, Stati Uniti, 27705
        • Reclutamento
        • Duke University Medical Center
        • Contatto:
    • North Dakota
      • Grand Forks, North Dakota, Stati Uniti, 58201
        • Completato
        • Altru Health Systems
    • Ohio
      • Cleveland, Ohio, Stati Uniti, 44106
      • Cleveland, Ohio, Stati Uniti, 44119
        • Ritirato
        • Cleveland Clinic
      • Columbus, Ohio, Stati Uniti, 42112
        • Reclutamento
        • The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solovev Research Institute (OSUCCC - James)
        • Contatto:
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Stati Uniti, 15232
        • Completato
        • University of Pittsburgh Medical Center
    • Texas
      • Houston, Texas, Stati Uniti, 77030
      • Houston, Texas, Stati Uniti, 77030
      • Houston, Texas, Stati Uniti, 77054
        • Reclutamento
        • Harris Health System - Smith Clinic
        • Investigatore principale:
          • Ahmed Elkhanany
        • Contatto:
    • Washington
      • Seattle, Washington, Stati Uniti, 98104
        • Ritirato
        • Swedish Cancer Institute (SCI)
      • Changhua, Taiwan
        • Reclutamento
        • Changhua Christian Hospital (CCH)
        • Contatto:
      • Kaohsiung City, Taiwan
        • Reclutamento
        • Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)
        • Contatto:
      • Tainan, Taiwan
        • Reclutamento
        • National Cheng Kung University Hospital
        • Contatto:
      • Taipei, Taiwan
        • Reclutamento
        • National Taiwan University Hospital
        • Contatto:
      • Taipei, Taiwan
        • Reclutamento
        • Tri-Service General Hospital
        • Contatto:
      • Taipei, Taiwan
        • Reclutamento
        • Koo Foundation Sun Yat-Sen Cancer Center
        • Contatto:
      • Taoyuan City, Taiwan
      • Ankara, Turchia (Türkiye)
        • Reclutamento
        • Ankara University Medical Faculty Medical Oncology Department
        • Contatto:
      • Bursa, Turchia (Türkiye)
        • Reclutamento
        • Uludag University Faculty of Medicine Hospital
        • Contatto:
      • Edirne, Turchia (Türkiye)
      • Izmir, Turchia (Türkiye)
    • Ankara
      • Çankaya, Ankara, Turchia (Türkiye)
    • Istanbul
      • Kadiköy, Istanbul, Turchia (Türkiye)
        • Reclutamento
        • Goztepe Prof. Dr. Suleyman Yalcin City Hospital
        • Contatto:
      • Çapa, Istanbul, Turchia (Türkiye)
    • Kocaeli
    • İzmir
      • Bornova, İzmir, Turchia (Türkiye)
        • Reclutamento
        • Ege University Medical Faculty Hospital
        • Contatto:
      • Konak, İzmir, Turchia (Türkiye)

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Pre- or postmenopausal women or men.

  2. Locally advanced and/or metastatic ER+ breast cancer with radiological or clinical evidence of progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease.

  3. Histological or cytological confirmation of ER+/HER2 - disease

  4. No evidence of progression for at least 6 months on an AI/CDKi combination for advanced breast cancer.

  5. At least 1 or more ESR1 point mutations in the ESR1 ligand binding domain as assessed in cell- free ctDNA obtained from a blood or breast cancer tissue.

  6. Locally advanced or metastatic breast cancer with at least 1 measurable (according to RECIST 1.1) lesion with or without non-measurable lesions.

  7. Subjects may have received 1 cytotoxic chemotherapy regimen in the metastatic disease setting prior to study entry, but must have recovered from chemotherapy acute toxicity excluding alopecia and Grade 2 peripheral neuropathy.

  8. Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1

  9. Adequate organ function

  10. Able to swallow tablets

  11. Brain metastases are allowed only if the following 4 parameters hold:

    1. Asymptomatic,
    2. Definitively treated (e.g., radiotherapy, surgery),
    3. Not requiring steroids up to 4 weeks before study treatment initiation, AND
    4. Central nervous system disease stable for >3 months prior to registration as documented by magnetic resonance imagining (MRI).
  12. Able to understand and voluntarily sign a written informed consent before any screening procedures.

  13. Every attempt should be made to obtain a biopsy of metastatic breast cancer tissue, when safe and feasible, to provide histological or cytological confirmation of ER+/HER2- disease as assessed by a local laboratory, according to American Society of Clinical Oncology/College of American Pathologists guidelines, using slides, paraffin blocks, or paraffin samples. If a biopsy is done, it may undergo genomic testing at some point to assess for ESR1 mutations and correlation with ctDNA results. If a biopsy is not possible or inappropriate from a clinical standpoint, the ER and HER2 status from the subject's most recent biopsy must confirm that the subject is ER+ and HER2

Exclusion Criteria:

  1. Lymphangitic carcinomatosis involving the lung.
  2. History of Grade 3 or Grade 4 interstitial lung disease (ILD) on previous therapy.
  3. Visceral crisis in need of cytotoxic chemotherapy as assessed by the investigator.
  4. Prior progression of disease on abemaciclib, fulvestrant, or other selective estrogen receptor degrader (SERD) therapy.
  5. Subjects with a known hypersensitivity to fulvestrant or to any of the excipients
  6. Radiotherapy within 30 days prior to Visit 0 (Day 1) except in case of localized radiotherapy for analgesic purposes or for lytic lesions at risk of fracture, which can then be completed within 7 days prior to Visit 0 (Day 1). Subjects must have recovered from radiotherapy toxicities prior to Visit 0 (Day 1).
  7. Known RB1 mutations or deletions that in the opinion of the investigator confer resistance to CDK4/6i. (Screening for RB1 mutation is not required for entry.)
  8. History of long QTc (Q-T interval corrected for heart rate) syndrome or a QTc of >480 msec.
  9. History of a pulmonary embolus (PE), deep vein thrombosis (DVT), or any known thrombophilia, unless the event occurred greater than 6 months prior to screening and the subject is treated with chronic anticoagulant therapy such as apixaban (Eliquis) or rivaroxaban (Xarelto).
  10. Lasofoxifene is not recommended for use in subjects with conditions that place them at increased risk for VTEs (such as severe congestive heart failure [CHF] or prolonged immobilization).
  11. On concomitant strong CYP3A4 inhibitors.
  12. On strong and moderate CYP3A4 inducers.
  13. Any significant co-morbidity that would impact the study or the subject's safety, including subjects with significant malabsorption.
  14. Active systemic bacterial or fungal infection (requiring intravenous [IV] antibiotics or antifungals at the time of initiating study treatment).
  15. Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV).
  16. History of malignancy within the past 5 years (excluding breast cancer), except basal cell or squamous cell carcinoma of the skin curatively treated by surgery.
  17. Positive serum pregnancy test (only if premenopausal).
  18. Sexually active premenopausal women and men unwilling to use double-barrier contraception.
  19. Women who are breast feeding
  20. History of non-compliance to medical regimens.
  21. Unwilling or unable to comply with the protocol.
  22. Current participation in any clinical research trial involving an investigational drug or device within the last 30 days.
  23. Subjects with a history of familial hypertriglyceridemia or fasting triglyceride levels >880 mg/dL at screening.
  24. Fasting triglyceride level >300 mg/dL and ≤880 mg/dL at screening. Subjects may be retested and enrolled if they have a repeat fasting triglyceride level less than or equal to 300 mg/dL prior to enrollment (e.g., after adjustment with diet and/or treatment).
  25. Fasting cholesterol level >400 mg/dL at screening. Subjects may be retested and enrolled if they have a repeat fasting cholesterol level less than or equal to 400 mg/dL prior to enrollment (e.g., after adjustment with diet and/or treatment).

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Treatment

Pre- and Postmenopausal Women and Men with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease and who have an ESR1 mutation.

5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day

Comparatore attivo: Reference Therapy

Pre- and Postmenopausal Women and Men with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease and who have an ESR1 mutation.

Fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Progression free survival (PFS)
Lasso di tempo: Within approximately 3 years

PFS is defined as the time from the date of randomization [Visit 0 (Day 1)] to the earliest date of first documented progression per RECIST 1.1 as determined by BICR or death due to any cause.

Within approximately 3 years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Objective response rate (ORR)
Lasso di tempo: Within approximately 3 years

ORR is defined as the percentage of subjects with measurable disease at baseline whose best overall response is either a confirmed CR or a confirmed PR according to RECIST 1.1.

Within approximately 3 years
Overall survival (OS)
Lasso di tempo: Within approximately 3 years

Overall survival is defined as time from the date of Visit 0 (Day 1) to death due to any cause.

Within approximately 3 years
Clinical benefit rate (CBR)
Lasso di tempo: Within approximately 3 years

CBR is defined as the percentage of subjects with best overall response of confirmed CR, confirmed PR, or stable disease (SD) with a duration of 24 weeks or longer according to RECIST 1.1. As used in this calculation, stable disease is defined as stable disease in those subjects with measurable disease plus nonPR/non progressive disease (PD) in subjects with non-measurable disease.

Within approximately 3 years
Duration of response (DoR) in subjects with an objective response
Lasso di tempo: Within approximately 3 years

DoR is from the date of first documented confirmed response (CR or PR) to the date of first documented progression of disease or death due to any cause, whichever is earlier.

Within approximately 3 years
Time to response (TTR) in subjects with an objective response
Lasso di tempo: Within approximately 3 years

TTR is from the date of randomization to the date of first documented confirmed response (CR or PR).

Within approximately 3 years
Time to cytotoxic chemotherapy
Lasso di tempo: Within approximately 3 years

From the date of randomization to the date of first documented use of cytotoxic chemotherapy.

Within approximately 3 years
Quality of Life (QoL) evaluated using the Functional Assessment of Cancer Therapy-Breast Cancer-Endocrine Subscale (FACT B-ES)
Lasso di tempo: Within approximately 3 years

Scale ranges from 'Not at all' to 'Very much'

Within approximately 3 years
Incidence of Adverse Events (AEs) and Serious AEs
Lasso di tempo: Within approximately 3 years

The type, severity (graded by Common Terminology Criteria for Adverse Events [CTCAE version 5.0]), course, duration, seriousness, and relationship to study treatment will be assessed at each visit

Within approximately 3 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

31 ottobre 2023

Completamento primario (Stimato)

1 aprile 2027

Completamento dello studio (Stimato)

1 aprile 2028

Date di iscrizione allo studio

Primo inviato

13 gennaio 2023

Primo inviato che soddisfa i criteri di controllo qualità

13 gennaio 2023

Primo Inserito (Effettivo)

25 gennaio 2023

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

13 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

10 novembre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • SMX 22-002

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .